A recent clinical trial reveals encouraging news for a Cushing’s disease treatment A poster from ENDO 2025 showed that osilodrostat provides sustained clinical benefits in Cushing’s patients who experienced positive outcomes by the end of the treatment period. Richard Auchus, MD, PhD, discusses how the data reinforces the drug’s use, which was well-tolerated for extended […]
